Effectiveness of teriparatide in enhancing bone formation and reducing aseptic loosening risks post-hip arthroplasty in patients with avascular necrosis

Ashish Arbat; Kandarp Thakkar

doi:10.18203/issn.2455-4510.IntJResOrthop20243897

Authors

Ashish Arbat Department of Orthopaedic and Joint Replacement surgeon, Phadnis Hospital, Pune, Maharashtra, India
Kandarp Thakkar Zydus Lifescience, Ahmedabad, Gujarat, India

DOI:

https://doi.org/10.18203/issn.2455-4510.IntJResOrthop20243897

Keywords:

Teriparatide, Hip arthroplasty, AVN, Bone formation, Aseptic loosening, OA

Abstract

Background: The hip joint's critical role in weight-bearing and mobility is often compromised by avascular necrosis (AVN), leading to osteoarthritis (OA). This study evaluates the impact of teriparatide, a synthetic parathyroid hormone analog, on bone formation and the risk of aseptic loosening in post-hip arthroplasty patients affected by AVN.

Methods: In this retrospective, single-centre study, 26 patients who underwent hip replacement surgery due to AVN between November 2021 and November 2023 were included. Participants were selected based on specific inclusion and exclusion criteria and received daily subcutaneous injections of teriparatide (20 μg) for six months. The study focused on assessing the efficacy of Teriparatide in mitigating prosthetic loosening and enhancing bone formation post-hip arthroplasty, alongside monitoring for adverse events.

Results: The cohort had a mean age of 37.63 years, predominantly male (77%). The median time for post-surgical pain onset was 31 days. After 3 months of teriparatide therapy, all patients showed a significant reduction in joint pain and swelling, with improved mobility. Radiographic evaluations demonstrated a decrease in previously observed radiolucent lines, indicating successful prosthesis integration. At the 6-month mark, tomosynthesis revealed no space between either the femoral head or hip components and the osteotomy load surfaces. No adverse events were reported during the therapy period.

Conclusions: Teriparatide-is a promising therapeutic agent for enhancing surgical outcomes in post-hip arthroplasty in patients with AVN. Its role in promoting bone formation and reducing aseptic loosening risks is significant, suggesting its potential in improving patient recovery and pre-empting postoperative complications.

Metrics

Metrics Loading ...

References

Kakaria H, Sharma A, Sebastian B. Total Hip Replacement in Avascular Necrosis of Femoral Head. Med J Armed Forces India. 2005;61(1):33-5.

Singh A, Das S, Chopra A, Danda D, Paul BJ, March L, et al. Burden of osteoarthritis in India and its states, 1990-2019: findings from the Global Burden of disease study 2019. Osteoarthritis Cartilage. 2022;30(8):1070-8.

Pal CP, Singh P, Chaturvedi S, Pruthi KK, Vij A. Epidemiology of knee osteoarthritis in India and related factors. Indian J Orthop. 2016;50(5):518-22.

Colibazzi V, Coladonato A, Zanazzo M, Romanini E. Evidence based rehabilitation after hip arthroplasty. Hip Int. 2020;30:20-9.

Kumar A, Goel S, Gupta R, Gupta BM. Osteoarthritis research in India: A scientometric assessment of publications output during 2007-16. Int J Information Dissemination Technol. 2017;7:157.

Bhattacharjee S, Ahlawat A, Prasad A, Das RK. Total Hip Arthroplasty in Ochronotic Arthropathy: A Case Report. J Orthop Case Rep. 2023;13:86-91.

Elsiwy Y, Jovanovic I, Doma K, Hazratwala K, Letson H. Risk factors associated with cardiac complication after total joint arthroplasty of the hip and knee: a systematic review. J Orthop Surg Res. 2019;14:15.

Lyu H, Zhao SS, Yoshida K, Sara KT, Chang X, Sagar UN, et al. Comparison of Teriparatide and Denosumab in Patients Switching From Long-Term Bisphosphonate Use. J Clin Endocrinol Metab. 2019;104:5611-20.

Quattrocchi E, Kourlas H. Teriparatide: a review. Clin Ther. 2004;26:841-54.

Li G, Su L, Huihui X, Yixiao C, Jiapeng D, Ao X, et al. Potential effects of teriparatide (PTH (1-34)) on osteoarthritis: a systematic review. Arthr Res Therapy. 2023;25(1):3.

Gallagher JC, Genant HK, Crans GG, Vargas SJ, Krege JH. Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. J Clin Endocrinol Metab. 2005;90:1583-7.

Langdahl BL, Silverman S, Fujiwara S, Ken S, Nicola N, Satoshi S, et al. Real-world effectiveness of teriparatide on fracture reduction in patients with osteoporosis and comorbidities or risk factors for fractures: Integrated analysis of 4 prospective observational studies. Bone. 2018;116:58-66.

Minisola S, Cipriani C, Grotta GD, Luciano C, Marco O, Piergianni B, et al. Update on the safety and efficacy of teriparatide in the treatment of osteoporosis. Ther Adv Musculoskelet Dis. 2019;11:1759720X19877994.

Hauser B, Alonso N, Riches PL. Review of Current Real-World Experience with Teriparatide as Treatment of Osteoporosis in Different Patient Groups. J Clin Med. 2021;10:1403.

Chaudhari Y. Teriparatide therapy in joint replacement surgery: mitigating complications and improving patient outcomes in osteoarthritis. Int J Res Orthopaed. 2024;10:118-22.

Vall H, Parmar M. Teriparatide. In: StatPearls. StatPearls Publishing: Treasure Island (FL). 2024.

Roy AN, Mazumdar I. Effects of Teriparatide Treatment on Bone Mineral Density in Patients With Osteoporosis: A Short-Term Dose-Response Study. Cureus. 2023;15:e45662.

Leder BZ. Parathyroid Hormone and Parathyroid Hormone-Related Protein Analogs in Osteoporosis Therapy. Curr Osteoporos Rep. 2017;15:110-9.

Tsai JN, Uihlein AV, Burnett-Bowie SM, Neer RM, Derrico NP, Lee H, et al. Effects of Two Years of Teriparatide, Denosumab, or Both on Bone Microarchitecture and Strength (DATA-HRpQCT study). J Clin Endocrinol Metabol. 2016;101(5):2023-30.